Back to results
US 2024/0076272 A1Published application
Activators of Heme Regulated Inhibitor Kinase (HRI)
AssigneeThe Brigham and Women S Hospital, Inc.
InventorsBertal Huseyin Aktas, Michael Chorev, Qingwen Zhang
Life of this patent
Estimating the term…
Abstract
The present application provides compounds that modulate the activity of one or more eIF2α kinases. Pharmaceutical compositions and methods of treating diseases related to one or more eIF2α kinases are also provided.
Claims21
1-43. (canceled)
A compound of Formula I:
- or a pharmaceutically acceptable salt thereof, wherein:
- Cy1 is selected from the group consisting of a C3-10 cycloalkyl ring and a 5-10 membered heteroaryl ring;
- R1, R2, R3, and R4 are each independently selected from the group consisting of H, halo, C1-6 alkyl, C1-6 haloalkyl, and cyano, wherein at least one of R1, R2, R3, and R4 is not H;
- provided that the compound of Formula I is not selected from the group consisting of:
1 more element
The compound of claim 1 selected from any one of the following compounds:
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.